PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015.In February 2018 reported that the primary endpoint has been achieved in the PRO 140 pivotal combination therapy trial in HIV infection.

Property Value
dbo:abstract
  • PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015.In February 2018 reported that the primary endpoint has been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. (en)
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-14 22:10:23Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 14929103 (xsd:integer)
dbo:wikiPageLength
  • 9264 (xsd:integer)
dbo:wikiPageModified
  • 2018-09-02 22:55:09Z (xsd:date)
dbo:wikiPageOutDegree
  • 25 (xsd:integer)
dbo:wikiPageRevisionID
  • 857773219 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • PRO 140 is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015.In February 2018 reported that the primary endpoint has been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. (en)
rdfs:label
  • PRO 140 (en)
owl:sameAs
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of